Lupus Trials News

The best and brightest are working toward finding better treatments and ultimately a cure for lupus. Read about how the most important influencers in the lupus community are effecting lupus research, along with other issues that matter most to you.

Lupus Research Alliance Appoints New Executive Vice President of Affiliate Lupus Therapeutics

NEW YORK, NY. January 17— The Lupus Research Alliance (LRA) is pleased to announce the appointment of Stacie J. Bell, PhD as Executive Vice President to lead Lupus Therapeutics (LT), the organization’s clinical research affiliate. An accomplished research scientist and organizational leader, Dr. Bell comes to Lupus Therapeutics with more than 25 years of experience […]

Promising Data Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

ACR Convergence 2022 Included LRA-Authored Research on Measures to Demonstrate Treatment Efficacy for Patients with Lupus NEW YORK, NY–November 8, 2022 — The Lupus Research Alliance and its affiliate Lupus Therapeutics will present data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus […]

Lupkynis® (voclosporin) Granted Marketing Authorization in the European Union for Lupus Nephritis

September 21, 2022 Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults with lupus nephritis, the kidney damage associated with lupus.  The drug had also been approved this past January in the U.S. to treat adults with lupus nephritis in combination with a background immunosuppressive medication in […]

New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

August, 2022 We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment […]

LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis

NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […]

Study Finds Booster Vaccine Significantly Lowered COVID-19 Infection Risk Among People with Lupus

July 14, 2022 The booster dose of the SARS-CoV-2 vaccine significantly enhanced  the degree of protection from COVID-19 infections for people with systemic lupus erythematosus according to a new study reported in The Lancet Rheumatology. People with lupus have been shown to be at high risk for COVID-19 due to the malfunction of their immune […]

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […]

Jane Salmon, MD – Determined to Help Pregnant Women Triumph Over Lupus

March 24, 2022 Recognized for her contributions to lupus during 2022’s Women’s History Month, Dr. Jane Salmon chose to specialize in lupus research because it was there that she felt she could be of greatest value.  “There were so many unknowns in lupus with all its complexity. Here was a disease primarily affecting young women […]

Judith James, MD, PhD Fulfills Childhood Dream to be a Doctor with Outstanding Career in Lupus Treatment and Research

March 14, 2022 Dr. Judith James has wanted to be a doctor since she was four years old. But it wasn’t until she met two teenage lupus patients in the ICU that she determined to specialize in lupus treatment and research. “Both girls were 19; I was 19; one lived and one died. I was […]

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY.  A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […]

Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of  OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued. The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II).  While SLE-BRAVE-I showed a significant […]

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […]

FDA Authorizes Evusheld Emergency Use to Prevent COVID-19 in Immunocompromised Patients

December 9, 2021 People with lupus can be immunocompromised because of the disease itself or medications that suppress the immune system and some may not be adequately protected from COVID-19. A new treatment will soon be available for them. Evusheld was granted Emergency Use Authorization for COVID-19 prevention by the U.S. Food and Drug Administration […]

Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis

December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis. The U.S. Food and Drug Administration approved Lupkynis arlier this year […]

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […]

A “Call to Arms” for the Lupus Community

August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […]

Two Studies Show COVID-19 Vaccines are Well-Tolerated Among Lupus Patients

August 12, 2021 In two recent studies, researchers found that the four COVID-19 vaccines are well-tolerated in lupus patients. Given that the Moderna and Pfizer vaccines are the first mRNA vaccines currently authorized for the emergency use in people, lupus researchers have since worked to answer questions specifically about potential side effects and whether these […]

Important Message from CEO Kenneth Farber: U.S. FDA Approves New Lupus Treatment

August 2, 2021 Dear Friend of the Lupus Research Alliance, As we reported this morning, the lupus community has much to celebrate with the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (brand name, Saphnelo™). As a first-in-class and only new treatment for systemic lupus erythematosus in a decade, this approval marks a major […]

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […]

Two New Drugs Receive FDA Approval

May 1, 2021 “This is a historic moment in lupus with two new drug approvals for lupus nephritis just over a month,” enthused Kenneth M. Farber, LRA President and CEO. The LRA is excited to share that the U.S. Food and Drug Administration (FDA) has approved the use of voclosporin (Lupkynis™) as the first oral […]

LRA Writes President Supporting Dr. Janet Woodcock for FDA Commissioner

March 31, 2021 As part of the LRA’s mission to accelerate development and availability of much-needed new diagnostics and treatments for lupus, the organization’s President and CEO, Mr. Kenneth M. Farber, submitted a letter to President Joseph Biden to express LRA’s strong support for Dr. Janet Woodcock to be nominated for Commissioner of the U.S. […]

LRA Congratulates Equillium on Positive Results of Study of Potential New Lupus Treatment

March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE).  This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […]

Join LRA’s Interactive, Virtual Lupus Clinical Trials Fair on April 8th!

Join LRA’s Interactive, Virtual Lupus Clinical Trials Fair on April 8th! ·    Learn more about an upcoming study LRA is doing on COVID-19 vaccines in people with lupus ·    Network and talk to people who’ve been in a lupus trial ·    Speak with the researchers conducting lupus trials near you ·    Compete for prizes…and MUCH MORE Click here to […]

Helping Overcome Lupus Effects on Mental Health

Updated March 11, 2022 Neuropsychiatric lupus affects 80-90% of people with lupus. In a video series hosted by the Young Leaders Board of the Lupus Research Alliance, Dr. Meggan Mackay explains How to know if you have neuropsychiatric lupus and offers ways to improve cognitive health.  Dr. Mackay also describes a clinical trial she is […]

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […]

End of content

No more pages to load